OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Qin on Upcoming Areas of Interest in RCC Research

November 28th 2023

Qian (Janie) Qin, MD, discusses upcoming areas of interest in the renal cell carcinoma armamentarium.

Dr Johnson on the Efficacy of RMC-6236 in KRAS-Mutant NSCLC

November 28th 2023

Melissa L. Johnson, MD, discusses the preliminary efficacy findings from the phase 1 RMC-6236-001 trial in patients with non–small cell lung cancer harboring KRAS mutations and details the significance of these findings for patients within the KRAS G12X-mutant NSCLC population.

Dr Phillips on the Shifting Treatment Paradigm For CAR T-Cell Therapy in LBCL

November 28th 2023

Adrienne Phillips, MD, MPH, discusses the impact of CAR T-cell therapy on the treatment paradigm for patients with large B-cell lymphoma, highlighting key advancements in the decision-making process for CAR T-cell therapy selection.

Dr Weber on the Prognostic Utility of ctDNA Dynamics in Melanoma

November 28th 2023

Jeffrey S. Weber, MD, PhD, discusses the use of circulating-tumor DNA dynamics when guiding treatment decision-making in melanoma, according to data from the phase 2b mRNA-4157-P201/KEYNOTE-942 trial.

Dr Bupathi on Treating Patients With RCC in Community vs Academic Settings

November 28th 2023

Manojkumar Bupathi, MD, MS, discusses treating patients with renal cell carcinoma in community vs academic settings.

Dr Torres on Treatment With ADCs in Breast Cancer

November 28th 2023

Mylin A. Torres, MD, discusses using antibody-drug conjugates (ADCs) to treat patients with breast cancer.

Dr Kasper on the FDA Approval of Nirogacestat in Desmoid Tumors

November 27th 2023

Bernd Kasper, MD, PhD, discusses the significance of the FDA approval of nirogacestat for patients with desmoid tumors.

Dr Ma on the Use of AKT Inhibitors vs PI3K Inhibitors in Breast Cancer

November 27th 2023

Cynthia Ma, MD, PhD, discusses the use of AKT inhibitors vs PI3K inhibitors in breast cancer.

Dr Ganesan on the Use of ctDNA Assays For MRD Detection in Cancer Care

November 27th 2023

Shridar Ganesan, MD, PhD, discusses the current limitations and advantages of leveraging circulating-tumor DNA to detect minimal residual disease in patients with cancer, as well as how ctDNA assays may address mechanisms of resistance in clinical practice.

Dr Habib on Developments in Palliative Care For Patients With Cancer

November 27th 2023

M. Hamza Habib, MD, JD, MBA, FACP, FAAHPM, FRCPI, MRCP, discusses the development of novel technology-based strategies to improve palliative cancer for patients with cancer.

Dr Barata on the Critical Updates for the Treatment of Advanced RCC in 2023

November 27th 2023

Pedro Barata, MD, MSc, discusses the biggest clinical trial updates to emerge for the treatment of patients with advanced renal cell carcinoma from the 2023 International Kidney Cancer Symposium.

Dr Hurwitz on the Feasibility of Utilizing CAR T-Cell Therapy in Solid Tumors

November 27th 2023

Michael Hurwitz, MD, PhD, discusses the feasibility of utilizing CAR T-cell therapies in patients with solid tumors, such as kidney cancers.

Dr Markman on the Role of PARP Inhibitors in Ovarian Cancer

November 24th 2023

Maurie Markman, MD, discusses the unique role of PARP inhibitors in the treatment of patients with ovarian cancer.

Dr Hamid on the Rationale For Investigating Fianlimab Plus Cemiplimab in Melanoma

November 23rd 2023

Omid Hamid, MD, director, Melanoma Program, The Angeles Clinic and Research Institute, Cedars-Sinai, discusses the rationale for a phase 1 trial of fianlimab plus cemiplimab in patients with advanced melanoma who have received prior adjuvant PD-1 inhibitors.

Dr Leslie on Outpatient CAR T-Cell Therapy Programs for Hematologic Malignancies

November 23rd 2023

Lori A. Leslie, MD, discusses the benefits of implementing CAR T-cell therapy programs for patients with hematologic malignancies and highlights the successes with administering CAR T-cell therapy that JTCC has experienced.

Dr Garmezy on the Treatment of Patients With Cancer in the Community Setting

November 22nd 2023

Benjamin Garmezy, MD, discusses the treatment of patients with cancer in the community care setting, highlighting the need to include those from this population in enrollment to clinical trials.

Dr Boland on the Emergence of KRAS G12C Inhibitors in mCRC

November 22nd 2023

Patrick Boland, MD, discusses the development of therapeutic strategies targeting KRAS G12C mutations in colorectal cancer.

Dr Davies on Addressing Global Gaps in Multiple Myeloma Care

November 22nd 2023

Faith E. Davies, MD, discusses strategies for rectifying global gaps and addressing unmet needs in multiple myeloma care.

Dr Zhang on the Evolution of the Use of Belzutifan in RCC

November 22nd 2023

Tian Zhang, MD, MHS, discusses the evolution of the use of belzutifan in renal cell carcinoma, highlighting which key oncologists have been involved in this research.

Dr Tan on the Use of the Signatera™ Assay in RCC

November 22nd 2023

Alan Tan, MD, discusses the ongoing potential utility of circulating tumor DNA in patients with renal cell carcinoma and highlights how this approach is being used in his own practice.